Spironolactone Tablet, Film Coated
Product Images NDC 51655-344

4 FDA label images from Northwind Health Company, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 51655-344). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 344 26 Master Bottle Label Approval Rev A 05 20)

Label (51655 344 26 Master Bottle Label Approval Rev A 05 20)
Spironolactone Tablets USP 100 mg film-coated tablets packaging label. The label indicates a bottle containing 90 tablets for oral use, manufactured by Northwind Health Company, LLC. It includes storage instructions, dosage referral to the package insert, and safety warnings about keeping out of reach of children and protecting from light.*
FDA Label Image

Figure 1 (Spironolactone Figure 1)

Figure 1 (Spironolactone Figure 1)
A Kaplan-Meier survival probability chart comparing Spironolactone and Placebo over a 48-month period. The probability is plotted on the y-axis and months on the x-axis, showing higher survival probability for Spironolactone compared to Placebo, with sample sizes of 822 and 841 respectively and a log-rank p-value less than 0.001.*
FDA Label Image

Figure 2 (Spironolactone Figure 2)

Figure 2 (Spironolactone Figure 2)
A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups related to Spironolactone versus placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot indicates comparative effectiveness with markers representing HR and CI, and sample sizes (N) and percentages for each subgroup.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure of spironolactone showing the molecular arrangement and bonds between atoms in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.